spacer
home > epc > summer 2002 > why, when and how to implement electronic data capture - core decision points
PUBLICATIONS
European Pharmaceutical Contractor

Why, When and How to Implement Electronic Data Capture - Core Decision Points

European pharmaceutical companies wishing to supply the US market are regulated by the US Food and Drug Administration (FDA). There has been a 10-year dialogue between the FDA and global drug manufacturers about the acceptance of and mechanisms for implementing validated electronic signatures to replace manual sign-off throughout the drug development and manufacturing process. This article reflects on the practical impact on European pharmaceutical companies of the regulation finally agreed between the FDA and the industry, affectionately known to all as 21 CFR Part 11.

Modern LIMS to Help Support 21 CFR Part 11

In the early 1990s, members of the pharmaceutical industry met with the US Department of Health and Human Services and the Food and Drug Association (FDA) to determine how a paperless record system could be accommodated under the current Good Manufacturing Practice (GMP) regulations. In March 1997, after a six-year iterative development process with the industry, the FDA issued the final rule. Following a five-month grace period, the rule became effective on 20th August 1997.

The rule sets forth the criteria under which the FDA considers electronic records and electronic signatures to be equivalent to paper records and handwritten signatures. The rule is an extension to the predicate rules for GXPs - GLP: 21 CFR 58 for laboratories; GMP: 21 CFR 211 for manufacturing; 21 CFR 820 for medical devices; and GCP: 21 CFR 320 for clinical environments. 21 CFR Part 11, the FDA's final rule on using electronic records and electronic signatures, affects all pharmaceutical companies in Europe that sell products in the US. Even for those who do not sell within the US now, this regulation is still very important because in the near future all regulatory authorities will be working according to a similar standard.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Peter Boogaard, European Applications Manager at Applied Biosystems

Peter Boogaard has been involved in the field of laboratory automation since the introduction of commercial LIMS systems in 1981. Additionally, his career path has included several positions within database companies, including Oracle and Informix Corp. He has been Product Manager for the Informatics LIMS business unit in the US.

Peter has held several positions within the European Informatics organisation, including marketing, new business development and manager professional services. Peter Boogaard's current responsibility is managing the European Applied Biosystems Marketing Intelligence group in the Netherlands.

Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm accelerates strategy to broaden service offering into commercial manufacturing

MedPharm Ltd, a leading contract provider of topical and transdermal product design and development services, has announced two new appointments to its Board to support plans to grow its commercial manufacturing services.
More info >>

White Papers

Time lapse photography to demonstrate the potential antimicrobial abilities of Dycem contamination control flooring

Dycem

A defined volume of bioluminescent reporter bacteria was deposited onto 20 mm x 20 mm coupons of Dycem flooring, vinyl tile and ITW Alma tacky mat. Through monitoring of bacterial bioluminescence, metabolic inhibition was observed on all three surfaces however the effect occurred more rapidly on Dycem flooring than on vinyl or ITW Alma. Recovery counts after three hours of exposure to the floor surfaces showed between a 65% and 100% decrease in the number of viable organisms recovered from Dycem flooring compared to controls. On vinyl and ITW Alma flooring, there were slight increases in the number of viable survivors recovered compared to controls. Dycem flooring inhibited the metabolic activity and reduced the number of viable survivors recovered of Salmonella enterica Serovar Typhimurium DT104 pGLITE. It remains unclear as to whether this effect is attributable to the impregnated biocide or rapid drying of the inoculum on this surface.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement